Dogwood Therapeutics completed enrollment of 239 patients in its randomized Phase 2b trial of Halneuron for chemotherapy-induced neuropathic pain, reaching the upper end of its planned target range. The company expects topline data in November 2026. HAL-CINP is evaluating Halneuron against placebo in patients with moderate to severe neuropathic pain caused by prior platinum- and/or taxane-based chemotherapy. Participants receive eight subcutaneous doses over 14 days and are followed for 28 days. The primary endpoint is the change from baseline to week four in weekly average daily 24-hour recall pain-intensity scores. The trial is being conducted at approximately 25 U.S. sites, with secondary measures covering sleep, fatigue, neuropathy symptoms and overall health. Dogwood said positive results would represent a significant milestone for the company and patients because there are no FDA (U.S. Food and Drug Administration) approved treatments for CINP. The company also said an interim analysis supports its confidence that Halneuron can improve pain compared with placebo, while noting that the trial’s results and future development remain subject to clinical, regulatory and financing risks.